inclisiran

Novartis' Q4 earnings clouded by regulatory setbacks on inclisiran, Zolgensma
Novartis' Q4 earnings clouded by regulatory setbacks on inclisiran, Zolgensma
Endpoints
Novartis
earnings
inclisiran
Zolgensma
Flag link:
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
FDA Refuses to Approve Novartis' $9.7 Billion Cholesterol Drug for Now
Motley Fool
Novartis
FDA
cholesterol
inclisiran
complete response letter
Flag link:
Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market
Novartis’ $9.7B PCSK9 drug nabs first OK — now comes the challenge of finding a market
Endpoints
Europe
Novartis
PCSK9
inclisiran
Flag link:
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Regeneron flashes ‘great advance' in the NEJM for that other cholesterol drug sitting at the FDA
Endpoints
Regeneron
inclisiran
RNAi
Novartis
New England Journal of Medicine
Flag link:
Go or no go? Valuable drugs set for FDA decisions
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
FDA
drug approvals
Novartis
inclisiran
Biomarin
valrox
Roche
risdiplam
GSK
belantamab mafodotin
Gilead Sciences
Galapagos
filgotinib
Flag link:
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
ACC: New owner Novartis presents pooled inclisiran data cutting LDL cholesterol by half
Fierce Biotech
Novartis
ACC
PCSK9 inhibitors
inclisiran
Flag link:
Novartis posts pivotal data ahead of FDA decision on $9.7B bet
Novartis posts pivotal data ahead of FDA decision on $9.7B bet
Fierce Biotech
Novartis
inclisiran
clinical trials
FDA
Flag link:
Blockbusters in waiting: drug launches to watch in 2020
Blockbusters in waiting: drug launches to watch in 2020
Pharmaforum
drug launches
Biohaven
rimegepant
Novartis
ofatumumab
Celgene
ozanimod
Akebia Therapeutics
vadadustat
Biomarin
valrox
Gilead Sciences
filgotinib
Novo Nordisk
oral semaglutide
inclisiran
Immunomedics
sacituzumab govitecan
AstraZeneca
Enhertu
Bristol-Myers Squibb
liso-cel
Flag link:
Novartis plots cardio trial in UK as London HQ opens
Novartis plots cardio trial in UK as London HQ opens
Pharmaforum
Novartis
clinical trials
London
UK
inclisiran
Flag link:
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen
Motley Fool
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Why Novartis Is Buying The Medicines Company For $9.7 Billion
Forbes
Novartis
Medicines Company
M&A
inclisiran
Flag link:
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
Amidst Novartis Takeover Rumors, The Medicines Company Announces Positive Cholesterol Data
BioSpace
The Medicines Company
Novartis
M&A
inclisiran
clinical trials
Flag link:
AHA: MedCo's PCSK9 rival inclisiran hits LDL
AHA: MedCo's PCSK9 rival inclisiran hits LDL
Fierce Biotech
AHA
The Medicines Company
inclisiran
Flag link:
The Medicines Company Surges on Positive Drug Trial Results
The Medicines Company Surges on Positive Drug Trial Results
Motley Fool
Medicines Company
inclisiran
clinical trials
Flag link:
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
MedCo Preps for FDA Filing as Cholesterol Drug Clears Last Two Tests
Xconomy
The Medicines Company
clinical trials
inclisiran
cholesterol
Flag link:
MedCo's PCSK9 challenger steals the show at ESC with winning data
MedCo's PCSK9 challenger steals the show at ESC with winning data
Fierce Pharma
Medicines Company
ESC
PCSK9 inhibitors
inclisiran
Repatha
Praluent
European Society of Cardiology
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
Xconomy
PCSK9 inhibitors
Medicines Company
inclisiran
insurers
Flag link:
Medicines Company's PCSK9 drug hits phase 3 efficacy goals
Medicines Company's PCSK9 drug hits phase 3 efficacy goals
Fierce Biotech
Medicines Company
inclisiran
clinical trials
Flag link:
Medicines Co. awaits its date with destiny
Medicines Co. awaits its date with destiny
Biopharma Dive
The Medicines Company
clinical trials
inclisiran
Flag link:

Pages